Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18375998 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Suspended Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
Conditions: Myocardial Infarction;   Acute Coronary Syndromes;   Unstable Angina;   Percutaneous Coronary Intervention
Interventions: Drug: Tirofiban (Aggrastat);   Drug: Placebo
2 Unknown  Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
Condition: Myocardial Infarction
Interventions: Other: abciximab followed by implantation of bare metal stent;   Other: abciximab and Sirolimus eluting stent;   Other: tirofiban and bare metal stent;   Other: tirofiban and sirolimus-eluting stent

Indicates status has not been verified in more than two years